We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

11 hedge funds and large institutions have $213K invested in Scinai Immunotherapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

22% more funds holding

Funds holding: 9 → 11 (+2)

1.21% less ownership

Funds ownership: 10.63% → 9.42% (-1.2%)

23% less capital invested

Capital invested by funds: $275K → $213K (-$62.6K)

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$16.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$6.29K
3
Millennium Management
Millennium Management
New York
+$5.47K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$722

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$56.3K
2
Wells Fargo
Wells Fargo
California
-$12

SCNI Hedge Fund Activity: Q1 2024 in Review

11 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2024, worth a combined $213K — down 23% from $275K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SCNI positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, adding an estimated $16.7K. The largest seller was Armistice Capital, cutting an estimated $56.3K.

  • 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2024, up from 9 in Q4 2023.
  • Funds reported $213K of Scinai Immunotherapeutics stock for Q1 2024, down 23% quarter-over-quarter.
  • 2 funds opened new Scinai Immunotherapeutics positions in Q1 2024 and 0 closed out, a net change of +2 holders.
  • The largest Scinai Immunotherapeutics buyer in Q1 2024 was Sabby Management, an estimated $16.7K added.
  • The largest Scinai Immunotherapeutics seller in Q1 2024 was Armistice Capital, an estimated $56.3K sold.

Based on aggregated 13F filings for Q1 2024.